Abstract:Abstract Introduction/Background Atopic dermatitis (AD) affects approximately 5-10% of adults worldwide, significantly burdening affected patients. Newer treatments for moderate-to-severe AD, including biologic therapies and Janus-kinase (JAK) inhibitors, are associated with varied levels of efficacy, safety, monitoring, and administration requirements. Yet, patient preferences for different treatment options are not well characterized. Objectives A discrete choice experiment (DCE) was designed to quantify the extent to which AD patients in the United States (US) value different treatment attributes. Methods An online DCE survey was conducted in June 2023. Eligible participants included US adults (≥ 18 years) with self-reported moderate-to-severe AD or experience with systemic therapy, diagnosed with AD for ≥1 year, with inadequate response to topical treatments. DCE attributes were selected based on qualitative interviews with patients and clinical input, including attributes related to efficacy (i.e., sustained improvement in skin appearance, itch control), safety (i.e., risk of respiratory infection, cancer, and heart problems), treatment administration, and blood test frequency. Participants were presented 12 choice tasks, each presenting two hypothetical treatment profiles, and selected one profile from each task that reflected their preferred option. A conditional logit regression model was used to assess patient preferences for attributes. Sensitivity analyses were conducted, excluding patients who failed validity tests. Results A diverse group of 300 participants completed the survey (mean age: 45 years; 22% non-white or mixed; 70% female; 66% employed). Approximately half received their first AD treatment of any kind 5 or more years ago (50%), had experienced severe symptoms (50%), and had experience with systemic therapy (52%). Participants preferred treatments with higher efficacy, lower risk of AEs, and less frequent blood tests (p < 0.05). Frequency and mode of administration (i.e., oral vs. injectable) did not impact preferences (p > 0.05). On average, participants were willing to accept a reduction of 35.4, 17.7, and 1.2 percentage points in the probability of achieving itch control to receive a treatment with 1 percentage point less risk of cancer, heart problems, and respiratory infections, respectively. Treatment attributes, from high to low relative importance, were itch control (38%), followed by risk of cancer (23%), risk of respiratory infections (18%), risk of heart problems (11%), sustained improvement in skin appearance (5%), blood test frequency (3%), and frequency and mode of administration (2%). Results were similar in sensitivity analyses, indicating the robustness of the findings. Conclusions Patients with moderate-to-severe AD preferred treatments that maximize itch control while minimizing the risk of AEs (cancer, respiratory infections, heart problems), whereas mode of administration had little impact on preferences. Understanding patients’ preferences may help improve shared decision-making.

Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan

Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan

Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia-Pacific Region

Treatment satisfaction in adults with atopic dermatitis: a cross-sectional, population-based study examining patient and physician perspectives in the US.

Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis

Quality of Care and Management of Atopic Dermatitis Across Different Levels of Healthcare-A Survey-Based Patient Experience

Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey

Quality of life in atopic dermatitis in Asian countries: a systematic review

691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment

Quality of Life and Burden of Moderate-to-Severe Atopic Dermatitis in Adult Patients Within the Asia-Pacific Region: A Cross-sectional Survey

546 - Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment

An Expansive Review

Perspectives of Japanese patients on psoriatic disease burden: Results from "Psoriasis and Beyond," the Global Psoriatic Disease Survey

405 Understanding patient experience and factors influencing patient preference in the treatment of moderate-to-severe atopic dermatitis through in-depth qualitative patient interviews

Impact of 1‐year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis

Patient-reported burden in adults with atopic dermatitis: an international qualitative study

Skin health survey on atopic dermatitis among Japanese children: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study

Patients' and caregivers' perspectives of the atopic dermatitis journey

A cross-sectional questionnaire survey involving physicians for the clarification of the diagnosis and current status of therapeutic intervention of psoriatic arthritis in Japan

The atopic dermatitis patient journey: insights from a qualitative study

Atopic Dermatitis Severity, Patient Perception of the Disease, and Personality Characteristics: How Are They Related to Quality of Life?